Liquid biopsies to evaluate early therapeutic response in colorectal cancer: Figure 1.

Circulating tumor DNA as an early marker of therapeutic response in patients with metastatic colorectal cancer

(2015) J. Tie et al.   ANNALS OF ONCOLOGY

Detection of Cancer DNA in Plasma of Patients with Early-Stage Breast Cancer

(2014) J. A. Beaver et al.   CLINICAL CANCER RESEARCH

Liquid Biopsies: Genotyping Circulating Tumor DNA

(2014) Luis A. Diaz et al.   JOURNAL OF CLINICAL ONCOLOGY

Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification

(2014) Bruce D. Cheson et al.   JOURNAL OF CLINICAL ONCOLOGY

Multi-marker analysis of circulating cell-free DNA toward personalized medicine for colorectal cancer

(2014) Florent Mouliere et al.   Molecular Oncology

Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies

(2014) C. Bettegowda et al.   Science Translational Medicine

Current Approaches and Challenges for Monitoring Treatment Response in Colon and Rectal Cancer

(2014) Elizabeth McKeown et al.   Journal of Cancer

Circulating Tumor DNA to Monitor Metastatic Breast Cancer

(2013)   NEW ENGLAND JOURNAL OF MEDICINE

Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer

(2012) Sandra Misale et al.   NATURE

Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria

(2009) J. D. Wolchok et al.   CLINICAL CANCER RESEARCH

Association of Computed Tomography Morphologic Criteria With Pathologic Response and Survival in Patients Treated With Bevacizumab for Colorectal Liver Metastases

(2009) Yun Shin Chun   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

(2008) E.A. Eisenhauer et al.   EUROPEAN JOURNAL OF CANCER

Circulating mutant DNA to assess tumor dynamics

(2008) Frank Diehl et al.   NATURE MEDICINE